Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana

Emilie Faway, Lise Musset, Stéphane Pelleau, Béatrice Volney, Jessica Casteras, Valérie Caro, Didier Menard, Sébastien Briolant, Eric Legrand

Résultats de recherche: Contribution à un journal/une revueArticle

Résumé

Background: Plasmodium vivax malaria is a major public health problem in French Guiana. Some cases of resistance to chloroquine, the first-line treatment used against P. vivax malaria, have been described in the Brazilian Amazon region. The aim of this study is to investigate a possible dispersion of chloroquine-resistant P. vivax isolates in French Guiana. The genotype, polymorphism and copy number variation, of the P. vivax multidrug resistance gene-1 (pvmdr1) have been previously associated with modification of the susceptibility to chloroquine. Methods: The pvmdr1 gene polymorphism was evaluated by sequencing and copy number variation was assessed by real-time PCR, in P. vivax isolates obtained from 591 symptomatic patients from 1997 to 2013. Results: The results reveal that 1.0% [95% CI 0.4-2.2] of French Guiana isolates carry the mutations Y976F and F1076L, and that the proportion of isolates with multiple copies of pvmdr1 has significantly decreased over time, from 71.3% (OR = 6.2 [95% CI 62.9-78.7], p < 0.0001) in 1997-2004 to 12.8% (OR = 0.03 [95% CI 9.4-16.9], p < 0.0001) in 2009-2013. A statistically significant relationship was found between Guf-A (harboring the single mutation T958M) and Sal-1 (wild type) alleles and pvmdr1 copy number. Conclusions: Few P. vivax isolates harboring chloroquine-resistant mutations in the pvmdr1 gene are circulating in French Guiana. However, the decrease in the prevalence of isolates carrying multiple copies of pvmdr1 might indicate that the P. vivax population in French Guiana is evolving towards a decreased susceptibility to chloroquine.

langueAnglais
Pages1-7
Nombre de pages7
journalMalaria Journal
Volume15
Numéro1
Les DOIs
étatPublié - 8 nov. 2016

Empreinte digitale

French Guiana
MDR Genes
Plasmodium vivax
Chloroquine
Vivax Malaria
Mutation
DNA Copy Number Variations
Gene Dosage
Genes
Real-Time Polymerase Chain Reaction
Public Health

Citer ceci

Faway, E., Musset, L., Pelleau, S., Volney, B., Casteras, J., Caro, V., ... Legrand, E. (2016). Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana. DOI: 10.1186/s12936-016-1595-9
Faway, Emilie ; Musset, Lise ; Pelleau, Stéphane ; Volney, Béatrice ; Casteras, Jessica ; Caro, Valérie ; Menard, Didier ; Briolant, Sébastien ; Legrand, Eric. / Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana. Dans: Malaria Journal. 2016 ; Vol 15, Numéro 1. p. 1-7
@article{9e4d45d012f74ce6a96199c9282ca937,
title = "Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana",
abstract = "Background: Plasmodium vivax malaria is a major public health problem in French Guiana. Some cases of resistance to chloroquine, the first-line treatment used against P. vivax malaria, have been described in the Brazilian Amazon region. The aim of this study is to investigate a possible dispersion of chloroquine-resistant P. vivax isolates in French Guiana. The genotype, polymorphism and copy number variation, of the P. vivax multidrug resistance gene-1 (pvmdr1) have been previously associated with modification of the susceptibility to chloroquine. Methods: The pvmdr1 gene polymorphism was evaluated by sequencing and copy number variation was assessed by real-time PCR, in P. vivax isolates obtained from 591 symptomatic patients from 1997 to 2013. Results: The results reveal that 1.0{\%} [95{\%} CI 0.4-2.2] of French Guiana isolates carry the mutations Y976F and F1076L, and that the proportion of isolates with multiple copies of pvmdr1 has significantly decreased over time, from 71.3{\%} (OR = 6.2 [95{\%} CI 62.9-78.7], p < 0.0001) in 1997-2004 to 12.8{\%} (OR = 0.03 [95{\%} CI 9.4-16.9], p < 0.0001) in 2009-2013. A statistically significant relationship was found between Guf-A (harboring the single mutation T958M) and Sal-1 (wild type) alleles and pvmdr1 copy number. Conclusions: Few P. vivax isolates harboring chloroquine-resistant mutations in the pvmdr1 gene are circulating in French Guiana. However, the decrease in the prevalence of isolates carrying multiple copies of pvmdr1 might indicate that the P. vivax population in French Guiana is evolving towards a decreased susceptibility to chloroquine.",
author = "Emilie Faway and Lise Musset and St{\'e}phane Pelleau and B{\'e}atrice Volney and Jessica Casteras and Val{\'e}rie Caro and Didier Menard and S{\'e}bastien Briolant and Eric Legrand",
year = "2016",
month = "11",
day = "8",
doi = "10.1186/s12936-016-1595-9",
language = "English",
volume = "15",
pages = "1--7",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",
number = "1",

}

Faway, E, Musset, L, Pelleau, S, Volney, B, Casteras, J, Caro, V, Menard, D, Briolant, S & Legrand, E 2016, 'Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana' Malaria Journal, VOL. 15, Numéro 1, p. 1-7. DOI: 10.1186/s12936-016-1595-9

Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana. / Faway, Emilie; Musset, Lise; Pelleau, Stéphane; Volney, Béatrice; Casteras, Jessica; Caro, Valérie; Menard, Didier; Briolant, Sébastien; Legrand, Eric.

Dans: Malaria Journal, Vol 15, Numéro 1, 08.11.2016, p. 1-7.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana

AU - Faway,Emilie

AU - Musset,Lise

AU - Pelleau,Stéphane

AU - Volney,Béatrice

AU - Casteras,Jessica

AU - Caro,Valérie

AU - Menard,Didier

AU - Briolant,Sébastien

AU - Legrand,Eric

PY - 2016/11/8

Y1 - 2016/11/8

N2 - Background: Plasmodium vivax malaria is a major public health problem in French Guiana. Some cases of resistance to chloroquine, the first-line treatment used against P. vivax malaria, have been described in the Brazilian Amazon region. The aim of this study is to investigate a possible dispersion of chloroquine-resistant P. vivax isolates in French Guiana. The genotype, polymorphism and copy number variation, of the P. vivax multidrug resistance gene-1 (pvmdr1) have been previously associated with modification of the susceptibility to chloroquine. Methods: The pvmdr1 gene polymorphism was evaluated by sequencing and copy number variation was assessed by real-time PCR, in P. vivax isolates obtained from 591 symptomatic patients from 1997 to 2013. Results: The results reveal that 1.0% [95% CI 0.4-2.2] of French Guiana isolates carry the mutations Y976F and F1076L, and that the proportion of isolates with multiple copies of pvmdr1 has significantly decreased over time, from 71.3% (OR = 6.2 [95% CI 62.9-78.7], p < 0.0001) in 1997-2004 to 12.8% (OR = 0.03 [95% CI 9.4-16.9], p < 0.0001) in 2009-2013. A statistically significant relationship was found between Guf-A (harboring the single mutation T958M) and Sal-1 (wild type) alleles and pvmdr1 copy number. Conclusions: Few P. vivax isolates harboring chloroquine-resistant mutations in the pvmdr1 gene are circulating in French Guiana. However, the decrease in the prevalence of isolates carrying multiple copies of pvmdr1 might indicate that the P. vivax population in French Guiana is evolving towards a decreased susceptibility to chloroquine.

AB - Background: Plasmodium vivax malaria is a major public health problem in French Guiana. Some cases of resistance to chloroquine, the first-line treatment used against P. vivax malaria, have been described in the Brazilian Amazon region. The aim of this study is to investigate a possible dispersion of chloroquine-resistant P. vivax isolates in French Guiana. The genotype, polymorphism and copy number variation, of the P. vivax multidrug resistance gene-1 (pvmdr1) have been previously associated with modification of the susceptibility to chloroquine. Methods: The pvmdr1 gene polymorphism was evaluated by sequencing and copy number variation was assessed by real-time PCR, in P. vivax isolates obtained from 591 symptomatic patients from 1997 to 2013. Results: The results reveal that 1.0% [95% CI 0.4-2.2] of French Guiana isolates carry the mutations Y976F and F1076L, and that the proportion of isolates with multiple copies of pvmdr1 has significantly decreased over time, from 71.3% (OR = 6.2 [95% CI 62.9-78.7], p < 0.0001) in 1997-2004 to 12.8% (OR = 0.03 [95% CI 9.4-16.9], p < 0.0001) in 2009-2013. A statistically significant relationship was found between Guf-A (harboring the single mutation T958M) and Sal-1 (wild type) alleles and pvmdr1 copy number. Conclusions: Few P. vivax isolates harboring chloroquine-resistant mutations in the pvmdr1 gene are circulating in French Guiana. However, the decrease in the prevalence of isolates carrying multiple copies of pvmdr1 might indicate that the P. vivax population in French Guiana is evolving towards a decreased susceptibility to chloroquine.

UR - http://www.scopus.com/inward/record.url?scp=84994589009&partnerID=8YFLogxK

U2 - 10.1186/s12936-016-1595-9

DO - 10.1186/s12936-016-1595-9

M3 - Article

VL - 15

SP - 1

EP - 7

JO - Malaria Journal

T2 - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

IS - 1

ER -

Faway E, Musset L, Pelleau S, Volney B, Casteras J, Caro V et al. Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana. Malaria Journal. 2016 nov. 8;15(1):1-7. Disponible �, DOI: 10.1186/s12936-016-1595-9